Article
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in…
Drug Design, Development and Therapy · 2017 · Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G
Key facts
| Title | Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy |
|---|---|
| First author | Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G |
| Journal | Drug Design, Development and Therapy |
| Published | Jul 5, 2017 |
| DOI | 10.2147/DDDT.S113500 |
| Devices mentioned | K852441, K854177, K854178, K854179, K854180, K854181, K854182, K854183, K854184, K854185, K854186, K854187 and 1 more |
| Product codes mentioned | CDT, CEO, CGA, CGX, CHH, CIG, CIS, CIX, CJE, CKA, KLB, KLS and 1 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1